NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

急性細菌性皮膚、皮膚組織感染疾病(ABSSSI)- 市場洞察,流行病學,市場預測 ∼2028年

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 868382
出版日期 按訂單生產 內容資訊 英文 225 Pages
商品交期: 2-10個工作天內
價格
急性細菌性皮膚、皮膚組織感染疾病(ABSSSI)- 市場洞察,流行病學,市場預測 ∼2028年 Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 按訂單生產內容資訊: 英文 225 Pages
簡介

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的急性細菌性皮膚、皮膚組織感染疾病(ABSSSI)市場調查,疾病概要和現行的治療方法,新藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,患病數、診斷數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 簡介

第2章 急性細菌性皮膚、皮膚組織感染疾病(ABSSSI)市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要

  • 簡介
  • 症狀
  • 病因
  • 危險因素
  • 病理學
  • 診斷

第4章 主要7個國家流行病學和患者人口

  • 總患病數
  • 患病數:性別
  • 患病數:各病型
  • 患病數:各臨床症狀
  • 診斷數和可治療的病例數

第5章 各國流行病學

  • 美國
    • 總患病數
    • 患病數:性別
    • 患病數:各病型
    • 患病數:各臨床症狀
    • 診斷數和治療可能的病例數
  • 歐盟5國
    • 假設和理論的根據
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 現行治療

  • 治療流程
  • 治療指南

第7章 已上市治療藥

  • 成藥清單
  • Dalvance - Durata Therapeutics
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 安全性和效果
    • 副作用
    • 產品簡介
  • Baxdela - Melinta Therapeutics

第8章 新藥

  • 關鍵交叉比較
  • MK-1986:Merck Sharp & Dohme Corp.
    • 法規的里程碑
    • 臨床開發
    • 產品簡介
    • 臨床實驗平台活動
  • MRX-I:MicuRx
  • Iclaprim:MotifBio

第9章 主要7個國家的急性細菌性皮膚、皮膚組織感染疾病(ABSSSI)市場

  • 主要調查結果
  • 市場分析
    • 市場概要
    • 市場規模的變化與預測

第10章 急性細菌性皮膚、皮膚組織感染疾病(ABSSSI):各國市場分析

  • 美國
    • 市場規模
    • 市場規模:各類醫藥品
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 日本

第11章 市場成長要素

第12章 市場障礙

第13章 調查手法

第14章 DelveInsight的服務內容

第15章 免責聲明

第16章 關於DelveInsight

目錄
Product Code: DIMI0371

DelveInsight's 'Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acute Bacterial Skin and Skin-Structure Infection in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Bacterial Skin and Skin-Structure Infection from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) - Disease Understanding and Treatment Algorithm

According to the U.S. Food and Drug Administration (FDA), ABSSSI is defined as a bacterial infection of skin with a lesion size area of ≥75 cm2 (lesion size measured by the area of redness, oedema or induration). ABSSSIs consist of the most frequently diagnosed skin infections worldwide. The symptoms observed in ABSSSI are extensive cellulitis, wound infection, major cutaneous abscesses, and burn infections. There are several pathogens that lead to ABSSSIs, such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and others.

The DelveInsight Acute Bacterial Skin and Skin-Structure Infection market report gives the thorough understanding of the Acute Bacterial Skin and Skin-Structure Infection by including details such as disease definition, causes, symptoms, risk factors, pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Bacterial Skin and Skin-Structure Infection in the US, Europe, and Japan.

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Epidemiology

The Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Population of Acute Bacterial Skin and Skin-Structure Infection, Gender-specific Incidence Cases of Acute Bacterial Skin and Skin-Structure Infection, Subtype-specific Incidence Cases of Acute Bacterial Skin and Skin-Structure Infection, Incidence cases of ABSSSI by Clinical Manifestations, Diagnosed and Treatable Cases of Acute Bacterial Skin and Skin-Structure Infection) scenario of Acute Bacterial Skin and Skin-Structure Infection in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

As per Kaye et al, a total of 1.8% of hospital admissions for the years 2005 through 2011 were for adult patients with a SSSI primary diagnosis. According to DelveInsight, the total number of incident population of Acute Bacterial Skin and Skin-Structure Infection will change from the study period 2017-2028.

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Drug Chapters

This segment of the Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

According to The Infectious Diseases Society of America (IDSA) guidelines for the treatment of skin and soft tissue infections in 2014, the treatment of typical cases of cellulitis (major subtype of ABSSSI) includes an oral antibiotic with activity against streptococci. Major treatment options for mild cases of non-purulent infections include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin. Oral and intravenous options for the treatment of ABSSSIs with activity against MRSA include several long-standing therapies, such as sulfamethoxazole-trimethoprim, clindamycin, minocycline, doxycycline, vancomycin, daptomycin, linezolid, ceftaroline, and telavancin. Antibiotics with activity against MRSA are considered when the infection is associated with penetrating trauma, such as IV drug use.

To meet the increasing demand for the treatment of Acute Bacterial Skin and Skin-Structure Infection, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the Incident population of Acute Bacterial Skin and Skin-Structure Infection & awareness of the disease. The overall dynamics of Acute Bacterial Skin and Skin-Structure Infection market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Merck Sharp & Dohme Corp., Motif Bio, MicuRx, Durata Therapeutics, Wockhardt and some others, will significantly increase the market during the forecast period (2019-2028).

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Outlook

The Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Acute Bacterial Skin and Skin-Structure Infection in 7MM is expected to change from 2019-2028.

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Acute Bacterial Skin and Skin-Structure Infection such as MK-1986 (Merck Sharp & Dohme Corp), Iclaprim (Motif Bio), MRX-I (MicuRx) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Acute Bacterial Skin and Skin-Structure Infection market.

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) market
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) market
  • To understand the future market competition in the Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) market.

Table of Contents

1. Report Introduction

2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) : Market Overview at a Glance

  • 2.1. 7 Major Market Size (%) of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) in 2017
  • 2.2. 7 Major Market Size (%) of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) in 2028

3. Disease Background and Overview: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)

  • 3.1. Introduction
  • 3.2. Causes
  • 3.3. Pathophysiology
  • 3.4. Symptoms
  • 3.5. Risk Factor
  • 3.6. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. 7MM Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
  • 4.2. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
  • 4.3. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
  • 4.4. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident cases by Clinical Manifestations (2017-2028)
  • 4.5. 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)

5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) : Country- Wise Epidemiology

  • 5.1. United States
    • 5.1.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
    • 5.1.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
    • 5.1.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
    • 5.1.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
    • 5.1.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
  • 5.2. EU-5
    • 5.2.1. Assumptions and Rationale
    • 5.2.2. Germany
      • 5.2.2.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
      • 5.2.2.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
      • 5.2.2.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
      • 5.2.2.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
      • 5.2.2.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
    • 5.2.3. France
      • 5.2.3.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
      • 5.2.3.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
      • 5.2.3.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
      • 5.2.3.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
      • 5.2.3.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
    • 5.2.4. Italy
      • 5.2.4.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
      • 5.2.4.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
      • 5.2.4.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
      • 5.2.4.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
      • 5.2.4.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
    • 5.2.5. Spain
      • 5.2.5.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
      • 5.2.5.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
      • 5.2.5.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
      • 5.2.5.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
      • 5.2.5.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
    • 5.2.6. United Kingdom
      • 5.2.6.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
      • 5.2.6.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
      • 5.2.6.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
      • 5.2.6.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
      • 5.2.6.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
  • 5.3. Japan
    • 5.3.1. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
    • 5.3.2. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
    • 5.3.3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
    • 5.3.4. ABSSSI Incident cases by Clinical Manifestations (2017-2028)
    • 5.3.5. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)

6. Treatments & Medical Practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Marketed drugs

  • 7.1. List of Marketed Drugs
  • 7.2. Dalvance - Durata Therapeutics
    • 7.2.1. Mechanism of action
    • 7.2.2. Regulatory Milestones
    • 7.2.3. Advantage and disadvantage
    • 7.2.4. Safety and efficacy
    • 7.2.5. Side effects
    • 7.2.6. Product profile
  • 7.3. Baxdela - Melinta Therapeutics
    • 7.3.1. Mechanism of action
    • 7.3.2. Regulatory Milestones
    • 7.3.3. Advantage and disadvantage
    • 7.3.4. Safety and efficacy
    • 7.3.5. Side effects
    • 7.3.6. Product profile

8. Emerging Therapies

  • 8.1. Key Cross Competition
  • 8.2. MK-1986: Merck Sharp & Dohme Corp.
    • 8.2.1. Regulatory Milestones
    • 8.2.2. Clinical Development
    • 8.2.3. Product Profile
    • 8.2.4. Clinical Pipeline Activity
      • 8.2.4.1. Ongoing Trials Information
      • 8.2.4.2. Clinical Trial by Phase
  • 8.3. MRX-I: MicuRx
    • 8.3.1. Regulatory Milestones
    • 8.3.2. Clinical Development
    • 8.3.3. Product Profile
    • 8.3.4. Clinical Pipeline Activity
      • 8.3.4.1. Ongoing Trials Information
      • 8.3.4.2. Clinical Trials by Phase
  • 8.4. Iclaprim: MotifBio
    • 8.4.1. Regulatory Milestones
    • 8.4.2. Clinical Development
    • 8.4.3. Product Profile
    • 8.4.4. Clinical Pipeline Activity
      • 8.4.4.1. Ongoing Trials Information
      • 8.4.4.2. Clinical Trial by Phase

9. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) : Market Size

  • 9.1. Key Findings
  • 9.2. Total 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Analysis
    • 9.2.1. Overview of Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market
    • 9.2.2. Market size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market by 7MM (2017-2028)

10. 7MM: Country-Wise Market Analysis

  • 10.1. United States Market Size
    • 10.1.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
    • 10.1.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
  • 10.2. Germany Market Size
    • 10.2.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
    • 10.2.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
  • 10.3. France Market Size
    • 10.3.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
    • 10.3.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
  • 10.4. United Kingdom Market Size
    • 10.4.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
    • 10.4.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
  • 10.5. Spain Market Size
    • 10.5.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
    • 10.5.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
  • 10.6. Italy Market Size
    • 10.6.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
    • 10.6.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies
  • 10.7. Japan Market Size
    • 10.7.1. Total Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)
    • 10.7.2. Market Size of Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) by Therapies

11. Market Drivers

12. Market Barriers

13. Report Methodology

  • 13.1. Sources Used

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables

  • Table 1: 7MM Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
  • Table 2:7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
  • Table 3:7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
  • Table 4: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident cases by Clinical Manifestations (2017-2028)
  • Table 5: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
  • Table 6: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United States (2017-2028)
  • Table 7: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in the United States (2017-2028)
  • Table 8: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in the United States (2017-2028)
  • Table 9: ABSSSI Incident cases by Clinical Manifestations in the United States (2017-2028)
  • Table 10: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in the United States (2017-2028)
  • Table 11: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Germany (2017-2028)
  • Table 12: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Germany (2017-2028)
  • Table 13: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Germany (2017-2028)
  • Table 14: ABSSSI Incident cases by Clinical Manifestations in Germany (2017-2028)
  • Table 15: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Germany (2017-2028)
  • Table 16: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in France (2017-2028)
  • Table 17: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in France (2017-2028)
  • Table 18: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in France (2017-2028)
  • Table 19: ABSSSI Incident cases by Clinical Manifestations in France (2017-2028)
  • Table 20: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in France (2017-2028)
  • Table 21: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Italy (2017-2028)
  • Table 22: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Italy (2017-2028)
  • Table 23: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Italy (2017-2028)
  • Table 24: ABSSSI Incident cases by Clinical Manifestations in Italy (2017-2028)
  • Table 25: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Italy (2017-2028)
  • Table 26: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Spain (2017-2028)
  • Table 27: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Spain (2017-2028)
  • Table 28: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Spain (2017-2028)
  • Table 29: ABSSSI Incident cases by Clinical Manifestations in Spain (2017-2028)
  • Table 30: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Spain (2017-2028)
  • Table 31: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United Kingdom (2017-2028)
  • Table 32: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases the United Kingdom (2017-2028)
  • Table 33: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases the United Kingdom (2017-2028)
  • Table 34: ABSSSI Incident cases by Clinical Manifestations the United Kingdom (2017-2028)
  • Table 35: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases the United Kingdom (2017-2028)
  • Table 36: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Japan (2017-2028)
  • Table 37: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Japan (2017-2028)
  • Table 38: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Japan (2017-2028)
  • Table 39: ABSSSI Incident cases by Clinical Manifestations in Japan (2017-2028)
  • Table 40: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Japan (2017-2028)
  • Table 41: MK-1986, Clinical Trials by Recruitment status, 2019
  • Table 42: MK-1986, Clinical Trials by Zone, 2019
  • Table 43: MRX-I, Clinical Trials by Recruitment status, 2019
  • Table 44: MRX-I, Clinical Trials by Zone, 2019
  • Table 45: Total 7 Major Market Size in USD, Million (2017-2028)
  • Table 46: Region wise Market Size in USD, Million (2017-2028)
  • Table 47: 7MM-Market Size by Therapy in USD, Million (2017-2028)
  • Table 48: United States Market Size in USD, Million (2017-2028)
  • Table 49: United States Market Size by Therapy in USD, Million (2017-2028)
  • Table 50: Germany Market Size in USD, Million (2017-2028)
  • Table 51: Germany Market Size by Therapy in USD, Million (2017-2028)
  • Table 52: France Market Size in USD, Million (2017-2028)
  • Table 53: France Market Size by Therapy in USD, Million (2017-2028)
  • Table 54: Italy Market Size in USD, Million (2017-2028)
  • Table 55: Italy Market Size by Therapy in USD, Million (2017-2028)
  • Table 56: Spain Market Size in USD, Million (2017-2028)
  • Table 57: Spain Market Size by Therapy in USD, Million (2017-2028)
  • Table 58: United Kingdom Market Size in USD, Million (2017-2028)
  • Table 59: United Kingdom Market Size by Therapy in USD, Million (2017-2028)
  • Table 60: Japan Market Size in USD, Million (2017-2028)
  • Table 61: Japan Market Size by Therapy in USD, Million (2017-2028)

List of Figures

  • Figure 1: 7MM Total Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases (2017-2028)
  • Figure 2: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases (2017-2028)
  • Figure 3: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases (2017-2028)
  • Figure 4: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident cases by Clinical Manifestations (2017-2028)
  • Figure 5: 7MM Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases (2017-2028)
  • Figure 6: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United States (2017-2028)
  • Figure 7: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in the United States (2017-2028)
  • Figure 8: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in the United States (2017-2028)
  • Figure 9: ABSSSI Incident cases by Clinical Manifestations in the United States (2017-2028)
  • Figure 10: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in the United States (2017-2028)
  • Figure 11: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Germany (2017-2028)
  • Figure 12: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Germany (2017-2028)
  • Figure 13: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Germany (2017-2028)
  • Figure 14: ABSSSI Incident cases by Clinical Manifestations in Germany (2017-2028)
  • Figure 15: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Germany (2017-2028)
  • Figure 16: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in France (2017-2028)
  • Figure 17: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in France (2017-2028)
  • Figure 18: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in France (2017-2028)
  • Figure 19: ABSSSI Incident cases by Clinical Manifestations in France (2017-2028)
  • Figure 20: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in France (2017-2028)
  • Figure 21: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Italy (2017-2028)
  • Figure 22: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Italy (2017-2028)
  • Figure 23: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Italy (2017-2028)
  • Figure 24: ABSSSI Incident cases by Clinical Manifestations in Italy (2017-2028)
  • Figure 25: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Italy (2017-2028)
  • Figure 26: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Spain (2017-2028)
  • Figure 27: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Spain (2017-2028)
  • Figure 28: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Spain (2017-2028)
  • Figure 29: ABSSSI Incident cases by Clinical Manifestations in Spain (2017-2028)
  • Figure 30: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Spain (2017-2028)
  • Figure 31: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in the United Kingdom (2017-2028)
  • Figure 32: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases the United Kingdom (2017-2028)
  • Figure 33: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases the United Kingdom (2017-2028)
  • Figure 34: ABSSSI Incident cases by Clinical Manifestations the United Kingdom (2017-2028)
  • Figure 35: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases the United Kingdom (2017-2028)
  • Figure 36: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Incident Cases in Japan (2017-2028)
  • Figure 37: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Gender-specific Incident Cases in Japan (2017-2028)
  • Figure 38: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Subtype-specific Incident Cases in Japan (2017-2028)
  • Figure 39: ABSSSI Incident cases by Clinical Manifestations in Japan (2017-2028)
  • Figure 40: Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Diagnosed and Treatable cases in Japan (2017-2028)
  • Figure 41: MK-1986, Clinical Trials by Recruitment status, 2019
  • Figure 42: MK-1986, Clinical Trials by Zone, 2019
  • Figure 43: MRX-I, Clinical Trials by Recruitment status, 2019
  • Figure 44: MRX-I, Clinical Trials by Zone, 2019
  • Figure 45: Total 7 Major Market Size in USD, Million (2017-2028)
  • Figure 46: Region wise Market Size in USD, Million (2017-2028)
  • Figure 47: 7MM-Market Size by Therapy in USD, Million (2017-2028)
  • Figure 48: United States Market Size in USD, Million (2017-2028)
  • Figure 49: United States Market Size by Therapy in USD, Million (2017-2028)
  • Figure 50: Germany Market Size in USD, Million (2017-2028)
  • Figure 51: Germany Market Size by Therapy in USD, Million (2017-2028)
  • Figure 52: France Market Size in USD, Million (2017-2028)
  • Figure 53: France Market Size by Therapy in USD, Million (2017-2028)
  • Figure 54: Italy Market Size in USD, Million (2017-2028)
  • Figure 55: Italy Market Size by Therapy in USD, Million (2017-2028)
  • Figure 56: Spain Market Size in USD, Million (2017-2028)
  • Figure 57: Spain Market Size by Therapy in USD, Million (2017-2028)
  • Figure 58: United Kingdom Market Size in USD, Million (2017-2028)
  • Figure 59: United Kingdom Market Size by Therapy in USD, Million (2017-2028)
  • Figure 60: Japan Market Size in USD, Million (2017-2028)
  • Figure 61: Japan Market Size by Therapy in USD, Million (2017-2028)